"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 8 | 7 | 15 |
| 1995 | 4 | 12 | 16 |
| 1996 | 2 | 17 | 19 |
| 1997 | 2 | 9 | 11 |
| 1998 | 4 | 7 | 11 |
| 1999 | 7 | 8 | 15 |
| 2000 | 3 | 7 | 10 |
| 2001 | 2 | 10 | 12 |
| 2002 | 1 | 4 | 5 |
| 2003 | 8 | 12 | 20 |
| 2004 | 9 | 12 | 21 |
| 2005 | 8 | 12 | 20 |
| 2006 | 11 | 3 | 14 |
| 2007 | 8 | 9 | 17 |
| 2008 | 10 | 4 | 14 |
| 2009 | 10 | 5 | 15 |
| 2010 | 5 | 5 | 10 |
| 2011 | 8 | 6 | 14 |
| 2012 | 4 | 1 | 5 |
| 2013 | 5 | 3 | 8 |
| 2014 | 2 | 4 | 6 |
| 2015 | 12 | 4 | 16 |
| 2016 | 5 | 3 | 8 |
| 2017 | 7 | 2 | 9 |
| 2018 | 8 | 3 | 11 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 6 | 2 | 8 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2023 Apr 13; 24(8).
-
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight. 2023 Mar 22; 8(6).
-
A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies. Biochem Pharmacol. 2023 04; 210:115470.
-
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023 01 12; 141(2):200-203.
-
Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturing. Biotechnol Bioeng. 2023 03; 120(3):715-725.
-
Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritis. Adv Rheumatol. 2022 05 27; 62(1):17.
-
IgG3 constant region GM (? marker) allotypes could influence the neutralizing potency of anti-SARS-CoV-2 monoclonal antibodies. Proc Natl Acad Sci U S A. 2022 02 08; 119(6).
-
Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. J Cardiovasc Pharmacol. 2021 11 01; 78(5):e631-e640.
-
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):326-335.
-
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.